Paige & OptraSCAN Partner to Streamline Digital Pathology Adoption

1. Paige and OptraSCAN Partner to Streamline Digital Pathology Adoption September 22, 2022 10:00 AM Eastern Daylight Time NEW YORK--(BUSINESS WIRE)--Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications, and OptraSCAN®, a leading producer of whole slide scanners, today announced a partnership to streamline the adoption of digital pathology technology in the United States, European Union countries and United Kingdom. The companies aim to reduce barriers to digitizing glass pathology slides, which will in turn enhance workflows in pathology and oncology. “This collaboration is an important step in our mission to unlock the full potential of AI in routine clinical use and provide healthcare professionals with precise insights to help patients get the most effective care.”

2. Together, the companies will integrate Paige’s clinical AI applications and interoperable enterprise imaging platform with OptraSCAN’s digital pathology scanner to offer advanced end- to-end digital pathology workflow solutions. This provides a streamlined path for pathologists to adopt Paige’s leading suite of digital pathology applications, including the FDA-cleared FullFocus® whole-slide image viewer and AI applications including Paige Prostate Suite and Paige Breast Suite alongside OptraSCAN’s affordable digital pathology scanners. OptraSCAN devices have 15 to 480 slide loading capabilities that digitize the glass slides at 40x in less than one minute per slide with patented composite imaging offering. “We are excited to work with OptraSCAN to make it easier for labs and healthcare networks around the world to adopt digital pathology workflows,” said Andy Moye, Ph.D., Chief Executive Officer at Paige. “This collaboration is an important step in our mission to unlock the full potential of AI in routine clinical use and provide healthcare professionals with precise insights to help patients get the most effective care.” Abhi Gholap, Founder and CEO of OptraSCANsaid, “OptraSCAN’s mission to enable pathology slide digitization at fractional costs is eventually resulting into higher market demand for digital pathology applications. This partnership with Paige will facilitate adoption of digital infrastructure for global clinical and molecular pathology community in an efficient way.” Explore how our solutions can specifically help you Schedule a Demo Download Brochure OptraSCAN® is an ISO13485 certified company. OptraSCAN® whole slide scanners are CE marked for IVDR use. OptraSCAN Systems are for research use only in North America.